Allarity Therapeutics Inc

Allarity Therapeutics, a Cambridge‑based oncology drug developer, faces volatile stock trends and a negative P/E ratio, but remains focused on advancing innovative cancer therapies amid investor uncertainty.

Allarity Therapeutics reports Q3 2025 results: modest cash decline, negative GAAP EPS of –$0.19, ongoing oncology pipeline, and a focus on securing new funding to advance its cancer therapeutics.